NRX Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
NRX Pharmaceuticals, Inc. (NRXP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.05% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-03-14
- NRX Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was 0.05%, a 72.22% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.18%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | 0.05% 10-K · filed 2025-03-14 |
| 2023-12-31 | 0.18% 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |